jueves, 7 de abril de 2016
Cancer Currents Blog: Early Drug Development Opportunity Program
Expanding Participation in NCI-supported Early-Phase Clinical Trials - National Cancer Institute
For many years, NCI has partnered with the pharmaceutical industry to develop new cancer therapies. Much of this work has focused on developing therapies that could be used to treat rare cancers, for which there is a great unmet need for effective agents. To enhance our drug development efforts NCI established the Experimental Therapeutics Clinical Trials Network(ETCTN) in 2013. As part of collaborations with pharmaceutical companies, NCI is currently developing more than 60 anticancer agents in ETCTN-supported clinical trials. ETCTN-funded investigators conduct early clinical studies of these agents, while NCI holds the regulatory approval from the Food and Drug Administration (FDA)—known as an IND—to test them. The ETCTN’s goal has been to expand the number of early-phase clinical trials of these promising new agents.